Estrogen receptor alpha gene analysis in osteoporosis and familial osteoporosis

Fountas, L.; Anapliotou, M.; Kominakis, A.; Sekeris, C.; Kassi, E.; Moutsatsou, P.
December 2004
Osteoporosis International;Dec2004, Vol. 15 Issue 12, p948
Academic Journal
Estrogens are important determinants of bone mineral density (BMD) mediating their effects via estrogen receptor a (ERa) and ß (ERß). The strong genetic predisposition to osteoporosis, and the fact that alterations in the aminoterminal region of ERa have been linked to bone disturbances, prompted us to identify genetic alterations in exon 1 and exon 2 of ERa in osteoporotic individuals. Sixty-two unrelated normal subjects (age 46.1±9.5 years) and 72 unrelated osteoporotic subjects (age 52.3±7.9 years) were studied. Their menopausal status was pre- and perimenopausal. We also included 30 related osteoporotic individuals (mother-daughter or sister-sister relationship) (age 46.2±12.8 years) belonging to 14 families who where also pre- and perimenopausal. DNA was extracted from peripheral blood, exons 1 and 2 were amplified by polymerase chain reaction (PCR) and were further submitted to denaturing gradient gel electrophoresis (DGGE), single stranded conformational polymorphism (SSCP), restriction fragment length polymorphism (RFLP) and sequence analysis. Bone turnover markers were also determined. Two polymorphisms were identified in exon 1 (codons 10 and 87) in both normal and osteoporotic women. Statistical analysis revealed no difference (P>0.05) in the ERa genotype frequencies within osteoporotic families as compared with the same genotypes in the unrelated normal or osteoporotic subjects. Codon 10, codon 87 polymorphisms were not related to BMD or bone turnover markers. No other mutations were found in exons 1 and 2 in all subjects studied. Genetic alterations in exons 1 and 2 of ERa are not associated to osteoporosis and familial osteoporosis. Moreover, the codon 10 and codon 87 polymorphisms do not seem to be correlated with BMD and bone turnover markers.


Related Articles

  • Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition). Nishizawa, Yoshiki; Ohta, Hiroaki; Miura, Masakazu; Inaba, Masaaki; Ichimura, Schoichi; Shiraki, Masataka; Takada, Junichi; Chaki, Osamu; Hagino, Hiroshi; Fujiwara, Saeko; Fukunaga, Masao; Miki, Takami; Yoshimura, Noriko // Journal of Bone & Mineral Metabolism;Jan2013, Vol. 31 Issue 1, p1 

    Recently the clinical application of bone metabolic markers has achieved significant progress and the measurements of these indices give us a better understanding of the pathogenesis of osteoporosis. Bone metabolic markers were adapted to select drug treatment for osteoporosis and to evaluate...

  • A specific haplotype in the 3′ end of estrogen-receptor alpha gene is associated with low bone mineral density in premenopausal women and increased risk of postmenopausal osteoporosis. Ongphiphadhanakul, B.; Chanprasertyothin, S.; Saetung, S.; Rajatanavin, R. // Osteoporosis International;Oct2005, Vol. 16 Issue 10, p1233 

    It is well established that the development of postmenopausal osteoporosis is under genetic influence. We have recently identified a synonymous single nucleotide polymorphism (SNP) in exon 8 of estrogen receptor-α (ERα) gene in the vicinity of the stop codon (G2014A) that is associated...

  • No Correlation with Intron 1 and Exon 1 Polymorphisms of ER-α.  // Fertility Weekly;1/5/2009, p10 

    The article focuses on a research conducted in Brazil, according to which, there is no relationship between endometriosis and polymorphisms of intron 1 and exon 1 of the estrogen receptor (ER) -αgene. In the presents study, researchers aimed to evaluate the association of intron 1 and exon 1...

  • Association of Estrogen Receptor α and Vitamin D Receptor Gene Polymorphisms with Bone Mineral Density in Chinese Males. Long, J. R.; Zhang, Y. Y.; Liu, P. Y.; Liu, Y. J.; Shen, H.; Dvornyk, V.; Zhao, L. J.; Deng, H. W. // Calcified Tissue International;Mar2004, Vol. 74 Issue 3, p270 

    Osteoporosis is a common health problem not only in females but also in males, however, studies of osteoporosis in males are relatively rare compared to those in females. This is especially true in genetics studies. We evaluated the effects of PvuII and XbaI polymorphisms in the estrogen...

  • Association of oestroqen receptor &alph;a gene polymorphisms with postmenopausal bone loss, bone mass, and quantitative ultrasound properties of bone. Albagha, O. M. E.; Peltersson, U.; Stewart, A.; McGuigan, F. E. A.; MacDonald, H. M.; Reid, D. M.; Ralston, S. H. // Journal of Medical Genetics;Mar2005, Vol. 42 Issue 3, p240 

    Background: The gene encoding oestrogen receptor α (ESR1) appears to regulate bone mineral density (BMD) and other determinants of osteoporotic fracture risk. Objective: To investigate the relation between common polymorphisms and haplotypes of the ESR1 gene and osteoporosis related...

  • Gene polymorphisms, bone mineral density and bone mineral content in young children:the Iowa bone development study. Marcia C. Willing; James C. Torner; Trudy L. Burns; Kathleen F. Janz; Teresa Marshall; Julie Gilmore; Sachi P. Deschenes; John J. Warren; Steven M. Levy // Osteoporosis International;Aug2003, Vol. 14 Issue 8, p650 

    We examined the association of candidate gene polymorphisms with bone mineral density (BMD) and bone mineral content (BMC) in a cohort of 428 healthy non-Hispanic white children participating in the Iowa Bone Development Study, a longitudinal study of determinants of bone accrual in childhood....

  • Evaluation of ERα and VDR gene polymorphisms in relation to bone mineral density in Turkish postmenopausal women. Kurt, Ozlem; Yilmaz-Aydogan, Hulya; Uyar, Mehmet; Isbir, Turgay; Seyhan, Mehmet; Can, Ayse // Molecular Biology Reports;Jun2012, Vol. 39 Issue 6, p6723 

    It has been suggested that the estrogen receptor alpha ( ERα) and vitamin D receptor ( VDR) genes as possibly implicated in reduced bone mineral density (BMD) in osteoporosis. The present study investigated the relation of ERα PvuII/ XbaI polymorphisms and VDR FokI/ TaqI polymorphisms with...

  • Novel agents in osteoporosis. Shah, H.D. // Indian Journal of Pharmacology;Feb2004, Vol. 36 Issue 1, p48 

    Discusses the different therapeutic agents for osteoporosis. Raloxifene; Strontium ranelate.

  • Biomechanics &mechanobiology (ASBMR 2012). Silva, Matthew J; Tomlinson, Ryan E // IBMS BoneKEy;Mar2013, Vol. 10 Issue 3, p282 

    Information about the topics on biomechanics and mechanobiology discussed at the 34th Annual Meeting of the American Society for Bone and Mineral Research in Minneapolis, Minnesota on October 12-15, 2012 is presented. The topics include diffuse damage repair, the role of raloxifene in improving...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics